Weian Zhao

Weian Zhao (赵伟安) is the founder and CEO of Aureka Biotechnologies (寻明生科), an AI-driven drug discovery company. Per 5Y Capital, the company closed a Series A of tens of millions of dollars in November 2025, with Zhao framing its thesis as "antibody drugs are not only to be 'discovered' — they can be designed" . In an August 2026 5Y piece on Aureka's $100 million Series B, he described the raise as a step toward combining biological foundation models with scalable R&D infrastructure to build "a next-generation drug discovery engine" . Qiming Venture Partners also reports that Aureka's agent platform AuraIDE™ can now design antibody molecules with clinical-grade functional characteristics from scratch, per Zhao . Beyond his role and these quoted remarks, elsewhere's corpus contains no further biographical detail on Zhao himself.